---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-054264"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2026-08-06T20:01:56+00:00"
generated_at: "2026-08-06T20:03:19.984485+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TriSalus Q2 revenue $11.4M (+1.7% YoY); maintains FY2026 guidance $54-57M

## Summary
- Revenue from TriNav system $11.4M, up 1.7% YoY; gross margin improved to 86.8% from 83.9%.
- Operating loss widened to $9.8M from $7.3M YoY on higher sales and marketing spend.
- Net loss $9.2M ($0.16 loss per share) vs $9.0M ($0.27 loss per share) in Q2 2025.
- Cash and equivalents $46.3M after $46.0M equity offering in Q1; runway sufficient for expansion.
- CMS established G-code for reimbursement of pressure-generating catheter in office-based labs.

## SEC filing metadata
- accession: 0001628280-26-054264
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2026-08-06T20:01:56+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000162828026054264/0001628280-26-054264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000162828026054264/tlsi-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-054264
- JSON: https://secwatch.observer/filing/0001628280-26-054264.json
- Plain text: https://secwatch.observer/filing/0001628280-26-054264.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.